Urine samples from adults with solid cancers to explore chemistry linked to nearing end of life
Official title: Metabolic Changes at End of Life
Run by The Clatterbridge Cancer Centre NHS Foundation Trust · NCT07848997 · Data updated 2026-11-12
This study tests urine chemistry in adults with solid tumors to see if it reflects how close a patient is to death.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1327 (estimated) |
| Sponsor | The Clatterbridge Cancer Centre NHS Foundation Trust Academic / other |
| Locations | 1 site (Liverpool, Merseyside) |
| Status | Recruiting |
| Started | May 1, 2026 |
| Main results expected | February 28, 2028 |
| Study ends | February 28, 2028 |
| Registry record updated | September 30, 2026 |
| Trial ID | NCT07848997 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with a solid tumor cancer who can understand English, can consent, and can provide urine (or be catheterised).
✕Probably not a fit
Patients whose cancer progression does not produce detectable urinary biomarkers or who cannot provide usable urine samples may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study collects urine samples from adults with a solid cancer diagnosis to analyze chemical patterns. It aims to identify biomarkers that may be associated with the dying process in cancer patients. The study design is non-interventional and relies on consenting participants to provide urine and basic clinical information. The research builds on existing observations that last-stage cancer involves systemic changes, but it seeks to characterize specific urinary signals related to imminent death. No interventions are described beyond sample collection and analysis of biospecimens.
Why it matters
Potential benefit: If successful, findings could improve understanding of dying processes in cancer and support future observational or diagnostic efforts.
How similar studies have gone: Previous work has identified systemic changes in end-of-life cancer, but direct urine-based dying biomarkers are exploratory and not yet proven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Must have as solid cancer tumour diagnosis Must be over the age of 18 Must be able to understand and communicate in English Must be able to provide fully informed consent at the point of trial entry Must be able to urinate freely or be catheterised Exclusion Criteria: * Does not have a solid cancer tumour diagnosis Under the age of 18 Unable to communicate and understand English Unable to provide fully informed consent at the point of trial entry Is no cathetherised or able to urinate freely
Where it's running
-
Clatterbridge Cancer Centre
Liverpool, Merseyside, United Kingdom Recruiting
Study contacts
- Study coordinator: Seamus Coyle Principal Investigator
- Email: s.coyle@liverpool.ac.uk
- Phone: 0151 556 5060
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Tempus Open Link registry for cancer patients using Olivia platform
This registry tests whether Olivia can securely enroll cancer patients and combine their health data from EHRs and patient-reported outcomes to build a large, de-identified dataset.
-
Metronomic low-dose gemcitabine, mitomycin C, and thalidomide for advanced solid tumors
This phase II trial tests a low-dose, continuously given combo of gemcitabine, mitomycin C, and thalidomide in adults with advanced solid tumors to see if it helps control the disease.
-
Imaging with 89Zr-DFO-YS5 to detect cancer
This study tests a new PET radiotracer, 89Zr-DFO-YS5, to see if it can show cancer sites in adults with nerve sheath tumors, bladder cancer, or other solid tumors.
-
JL19001 Injection Alone or with Standard Therapy in Advanced Solid Tumors or Relapsed/Refractory B-Cell NHL
This phase 1 trial tests JL19001 by itself or with standard treatment to see if it is safe and tolerable in adults with advanced solid tumors or relapsed/refractory B-cell non-Hodgkin lymphoma.
-
Phase 1 dose-escalation and expansion test of IUAb190708 for advanced or recurrent solid tumors
This trial tests IUAb190708, a new cytotoxic anti–PD‑L1 antibody given by IV, to see if it is safe and can kill tumors in adults with advanced or recurrent solid cancers.
-
IL-22BP mRNA peptide therapy for advanced solid tumors
A phase 1 study tests a new peptide-delivered IL-22BP mRNA treatment to see if it is safe and if it has any early signs of shrinking or stopping advanced solid tumors in adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.